Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference

Terns Pharmaceuticals, a clinical-stage biopharmaceutical company focused on serious diseases like non-alcoholic steatohepatitis (NASH), will showcase its progress at upcoming investor conferences.

Rhea-AI Summary

Terns Pharmaceuticals, a clinical-stage biopharmaceutical company focused on serious diseases like non-alcoholic steatohepatitis (NASH), will showcase its progress at upcoming investor conferences. The key events are the 40th Annual J.P. Morgan Health Care Conference on January 13, 2022, at 11:15 a.m. ET, and the H.C. Wainwright BioConnect 2022 Virtual Conference on January 10, 2022, at 7:00 a.m. ET. Interested parties can access live audio webcasts and replays on Terns' investor relations website.

Argus Session date unavailable

-1.94% session move Open Argus

Details

News Market Reaction – TERN

The recorded move for TERN in the trading session of this news was -1.94%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FOSTER CITY, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), today announced that the Company’s management team will present at the following investor conferences in January:

40th Annual J.P. Morgan Health Care Conference

• Date: January 13, 2022
• Time: 11:15 a.m. ET

H.C. Wainwright BioConnect 2022 Virtual Conference

• Date: January 10, 2022
• Time: 7:00 a.m. ET

A live audio webcast of each presentation will be available on the investor relations page of Terns’ website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days following the presentation.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis, or NASH. Terns’ pipeline includes three clinical stage development programs including an FXR agonist, a VAP-1 inhibitor and a THR-β agonist, and a preclinical small-molecule GLP-1 receptor agonist program. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What conferences will Terns Pharmaceuticals present at in January 2022?

Terns Pharmaceuticals will present at the 40th Annual J.P. Morgan Health Care Conference on January 13, 2022, and the H.C. Wainwright BioConnect 2022 Virtual Conference on January 10, 2022.

What time will Terns' presentations take place?

The presentation at the H.C. Wainwright BioConnect 2022 Virtual Conference will be on January 10, 2022, at 7:00 a.m. ET, and at the 40th Annual J.P. Morgan Health Care Conference on January 13, 2022, at 11:15 a.m. ET.

Where can I find the live audio webcast of Terns' presentations?

Live audio webcasts of Terns' presentations will be available on their investor relations page at http://ir.ternspharma.com.

What disease areas does Terns Pharmaceuticals focus on?

Terns Pharmaceuticals focuses on serious diseases, particularly non-alcoholic steatohepatitis (NASH), through its development of small-molecule therapies.